

Alan C Bird

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2267285/publications.pdf>

Version: 2024-02-01

75
papers

7,571
citations

81900

39
h-index

95266

68
g-index

77
all docs

77
docs citations

77
times ranked

5600
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement C3 Variant and the Risk of Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2007, 357, 553-561.	27.0	762
2	Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT. <i>Ophthalmology</i> , 2018, 125, 537-548.	5.2	485
3	Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. <i>Nature Genetics</i> , 1993, 3, 213-218.	21.4	483
4	A single EFEMP1 mutation associated with both Malattia Leventinese and Doyme honeycomb retinal dystrophy. <i>Nature Genetics</i> , 1999, 22, 199-202.	21.4	453
5	Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. <i>Nature Genetics</i> , 2000, 25, 462-466.	21.4	392
6	Macular telangiectasia type 2. <i>Progress in Retinal and Eye Research</i> , 2013, 34, 49-77.	15.5	311
7	Ageing Changes in Bruch's Membrane. <i>Ophthalmology</i> , 1990, 97, 171-178.	5.2	279
8	Relationship between Melatonin Rhythms and Visual Loss in the Blind. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3763-3770.	3.6	227
9	A mutation in NRL is associated with autosomal dominant retinitis pigmentosa. <i>Nature Genetics</i> , 1999, 21, 355-356.	21.4	205
10	Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16651-16656.	7.1	201
11	Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss. <i>American Journal of Ophthalmology</i> , 2002, 133, 341-349.	3.3	179
12	Correlation between Biochemical Composition and Fluorescein Binding of Deposits in Bruch's Membrane. <i>Ophthalmology</i> , 1992, 99, 1548-1553.	5.2	165
13	Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2017, 124, 464-478.	5.2	164
14	Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. <i>Progress in Retinal and Eye Research</i> , 2016, 53, 70-106.	15.5	159
15	Therapeutic targets in age-related macular disease. <i>Journal of Clinical Investigation</i> , 2010, 120, 3033-3041.	8.2	154
16	Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 394-409.	5.2	153
17	Sorsby's Fundus Dystrophy. <i>Ophthalmology</i> , 1989, 96, 1769-1777.	5.2	149
18	Geographic Atrophy. <i>JAMA Ophthalmology</i> , 2014, 132, 338.	2.5	144

#	ARTICLE	IF	CITATIONS
19	Photopic and Scotopic Fine Matrix Mapping of Retinal Areas of Increased Fundus Autofluorescence in Patients with Age-Related Maculopathy. , 2004, 45, 574.		141
20	Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiology, 2010, 17, 66-73.	1.7	132
21	Correlation between Lipids Extracted from Bruch's Membrane and Age. Ophthalmology, 1993, 100, 47-51.	5.2	128
22	High concentration of zinc in sub-retinal pigment epithelial deposits. Experimental Eye Research, 2007, 84, 772-780.	2.6	117
23	Distribution of pigment epithelium autofluorescence in retinal disease state recorded in vivo and its change over time. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 1-9.	1.9	113
24	Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2. Ophthalmology, 2019, 126, 540-549.	5.2	110
25	The Prevalence of Age-Related Maculopathy in Iceland. JAMA Ophthalmology, 2003, 121, 379.	2.4	107
26	Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial deposit formation in the aging eye. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1565-1570.	7.1	101
27	En face OCT Imaging of the IS/OS Junction Line in Type 2 Idiopathic Macular Telangiectasia. , 2012, 53, 6145.		98
28	Sorsby's Fundus Dystrophy. Ophthalmology, 1989, 96, 1763-1768.	5.2	97
29	The Pathogenesis of Tears of the Retinal Pigment Epithelium. American Journal of Ophthalmology, 1988, 105, 285-290.	3.3	87
30	Histopathology of Incipient Fundus Flavimaculatus. Ophthalmology, 1991, 98, 953-956.	5.2	80
31	Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial. American Journal of Ophthalmology, 2015, 159, 659-666.e1.	3.3	72
32	Perspectives on reticular pseudodrusen in age-related macular degeneration. Survey of Ophthalmology, 2016, 61, 521-537.	4.0	72
33	The IS/OS Junction Layer in the Natural History of Type 2 Idiopathic Macular Telangiectasia. , 2012, 53, 7889.		70
34	Dominantly inherited drusen represent more than one disorder: A historical review. Eye, 1995, 9, 34-41.	2.1	67
35	The X-linked retinopathies: Physiological insights, pathogenic mechanisms, phenotypic features and novel therapies. Progress in Retinal and Eye Research, 2021, 82, 100898.	15.5	65
36	Peripheral Retinal Imaging Biomarkers for Alzheimer's Disease: A Pilot Study. Ophthalmic Research, 2018, 59, 182-192.	1.9	64

#	ARTICLE	IF	CITATIONS
37	LONGITUDINAL CORRELATION OF ELLIPSOID ZONE LOSS AND FUNCTIONAL LOSS IN MACULAR TELANGIECTASIA TYPE 2. <i>Retina</i> , 2018, 38, S20-S26.	1.7	58
38	CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2. <i>Retina</i> , 2018, 38, S8-S13.	1.7	51
39	Localisation of a gene for dominant cone-rod dystrophy (CORD6) to chromosome 17p. <i>Human Molecular Genetics</i> , 1997, 6, 597-600.	2.9	50
40	Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2) MacTel Project Report No. 3. <i>Ophthalmic Epidemiology</i> , 2013, 20, 109-113.	1.7	50
41	Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. <i>Human Mutation</i> , 1994, 3, 409-410.	2.5	46
42	A Population-Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like Lesions at the Peripheral Retina. <i>Ophthalmology</i> , 2015, 122, 1340-1347.	5.2	44
43	Macular Pigment Parameters in Patients with Macular Telangiectasia (MacTel) and Normal Subjects: Implications of a Novel Analysis. , 2012, 53, 6568.		42
44	MULTIMODAL IMAGING IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. <i>Retina</i> , 2015, 35, 742-749.	1.7	35
45	The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular Study. <i>Acta Ophthalmologica</i> , 2006, 84, 636-641.	0.3	33
46	CHARACTERISTICS OF PIGMENTED LESIONS IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. <i>Retina</i> , 2018, 38, S43-S50.	1.7	28
47	Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19. <i>American Journal of Ophthalmology</i> , 2020, 216, A5-A6.	3.3	27
48	ABNORMAL RETINAL REFLECTIVITY TO SHORT-WAVELENGTH LIGHT IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. <i>Retina</i> , 2018, 38, S79-S88.	1.7	26
49	Retinal pigment epithelium translocation and central visual function in age related macular degeneration: preliminary results. <i>International Ophthalmology</i> , 2001, 23, 297-307.	1.4	24
50	The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 209-214.	1.9	23
51	CORRELATION OF STRUCTURAL AND FUNCTIONAL OUTCOME MEASURES IN A PHASE ONE TRIAL OF CILIARY NEUROTROPHIC FACTOR IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. <i>Retina</i> , 2018, 38, S27-S32.	1.7	23
52	Novel frameshift mutations in the RP2 gene and polymorphic variants. <i>Human Mutation</i> , 2000, 15, 580-580.	2.5	22
53	Electroretinogram measures in a septuagenarian population. <i>Documenta Ophthalmologica</i> , 2011, 123, 75-81.	2.2	22
54	Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. <i>Acta Ophthalmologica</i> , 2019, 97, e998-e1005.	1.1	22

#	ARTICLE	IF	CITATIONS
55	NRL S50T mutation and the importance of "founder effects"™ in inherited retinal dystrophies. <i>European Journal of Human Genetics</i> , 2000, 8, 783-787.	2.8	18
56	Refined genetic and physical positioning of the gene for Doyme honeycomb retinal dystrophy (DHRD). <i>Human Genetics</i> , 1999, 104, 77-82.	3.8	15
57	Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1453-1460.	1.9	14
58	Role of retinal pigment epithelium in age-related macular disease: a systematic review. <i>British Journal of Ophthalmology</i> , 2021, 105, 1469-1474.	3.9	14
59	A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in Healthy Ageing and Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2020, 9, 1001.	2.4	14
60	Treatment of pigment epithelial detachments due to age-related macular degeneration with intravitreal C ₃ F ₈ injection*. <i>Australian and New Zealand Journal of Ophthalmology</i> , 1998, 26, 311-317.	0.4	13
61	SCOTOMA CHARACTERISTICS IN MACULAR TELANGIECTASIA TYPE 2. <i>Retina</i> , 2018, 38, S14-S19.	1.7	13
62	Novel mutations of the RGR gene in RP3 families. <i>Human Mutation</i> , 2000, 15, 386-386.	2.5	12
63	Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2. <i>British Journal of Ophthalmology</i> , 2021, 105, 573-576.	3.9	10
64	Familial pars planitis and dominant optic atrophy. <i>Ophthalmic Genetics</i> , 1997, 18, 43-45.	1.2	7
65	Reanalysis of Association of Pro50Leu Substitution in Guanylate Cyclase Activating Protein-1 With Dominant Retinal Dystrophy. <i>JAMA Ophthalmology</i> , 2020, 138, 200.	2.5	5
66	Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging and age-related macular degeneration. <i>Scientific Reports</i> , 2021, 11, 10349.	3.3	5
67	How to keep photoreceptors alive. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2033-2034.	7.1	4
68	What Should a Clinician Know to be Prepared for the Advent of Treatment of Retinal Dystrophies?. <i>Novartis Foundation Symposium</i> , 2008, , 85-94.	1.1	3
69	Exploratory Study on Visual Acuity and Patient-Perceived Visual Function in Patients with Subretinal Drusenoid Deposits. <i>Journal of Clinical Medicine</i> , 2020, 9, 2832.	2.4	3
70	Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits—a pilot study. <i>Eye</i> , 2021, , .	2.1	3
71	Intermediate uveitis associated with familial Mediterranean fever. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S170.	0.8	2
72	Pathogenetic Mechanisms in Age-Related Macular Degeneration. , 2013, , 1145-1149.		1

#	ARTICLE	IF	CITATIONS
73	Unusual Retinal Vascular Proliferation in von Hippel-Lindau Disease. JAMA Ophthalmology, 2016, 134, 1073.	2.5	1
74	The ABCA4 2588G>C Stargardt mutation: single origin and increasing frequency from South-West to North-East Europe. , 0, .		1
75	What should a clinician know to be prepared for the advent of treatment of retinal dystrophies?. Novartis Foundation Symposium, 2004, 255, 85-90; discussion 90-4, 177-8.	1.1	1